Verastem Oncology Competitors and Similar CompaniesClear all
Verastem Oncology's competitors and similar companies include Novartis and Relay Therapeutics.
 Verastem Oncology Verastem Oncology is a biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with cancer. |  Novartis Novartis is a company that researches, develops, manufactures, and markets healthcare products. |  Relay Therapeutics Relay Therapeutics was founded on the premise that putting protein motion at the heart of drug discovery can dramatically expand therapeutic possibilities. | |
Founding Date | Founding Date 2010 | Founding Date 1996 | Founding Date 2016 |
Type | Type Public | Type Public | Type Public |
Tags | |||
Locations | Locations Needham, US HQ Walsrode, DE | Locations Basel, CH HQ Tirana, AL Buenos Aires, AR Macquarie Park, AU Kundl, AT Unterlangkampfen, AT Wien, AT see more | Locations Cambridge, US HQ |
Employees | Employees 7328% increase | Employees 75,883 | Employees 2724% decrease |
Valuation ($) | Valuation ($) 144.9 m | Valuation ($) N/A | Valuation ($) 958.5 m |
Financial | |||
Revenue (est.) | Revenue (est.) $30.9m (FY, 2025) | Revenue (est.) $56.7b (FY, 2025) | Revenue (est.) $15.4m (FY, 2025) |
Net income | Net income ($209.5m) (FY, 2025) | Net income $14b (FY, 2025) | Net income ($276.5m) (FY, 2025) |
Operating ⚠ | |||
Phase I/II Trials Products | Phase I/II Trials Products 6 (FY, 2020) | Phase I/II Trials Products 100 (FY, 2022) | Phase I/II Trials Products N/A |
Funding | |||
Total funding raised | Total funding raised $ 170m | Total funding raised $ 6.5m | Total funding raised $ 520m |
For sources of this data, please see the company profile
View Company Profiles
Novartis
HQ
Basel, CH
Employees
75,883
Novartis is a company that researches, develops, manufactures, and markets healthcare products.
View companyRelay Therapeutics
HQ
Cambridge, US
Employees
272↓ 4% decrease
Relay Therapeutics was founded on the premise that putting protein motion at the heart of drug discovery can dramatically expand therapeutic possibilities.
View company